These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31916187)

  • 1. Reappraisal of Inflammatory Biomarkers in Heart Failure.
    Chaikijurajai T; Tang WHW
    Curr Heart Fail Rep; 2020 Feb; 17(1):9-19. PubMed ID: 31916187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Inflammasomes in Heart Failure.
    Vlachakis PK; Theofilis P; Kachrimanidis I; Giannakopoulos K; Drakopoulou M; Apostolos A; Kordalis A; Leontsinis I; Tsioufis K; Tousoulis D
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.
    Abubakar M; Irfan U; Abdelkhalek A; Javed I; Khokhar MI; Shakil F; Raza S; Salim SS; Altaf MM; Habib R; Ahmed S; Ahmed F
    J Cardiovasc Transl Res; 2024 Jul; ():. PubMed ID: 38995611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Necrosis Factor-α in Heart Failure: an Updated Review.
    Schumacher SM; Naga Prasad SV
    Curr Cardiol Rep; 2018 Sep; 20(11):117. PubMed ID: 30259192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation in heart failure: pathophysiology and therapeutic strategies.
    Boulet J; Sridhar VS; Bouabdallaoui N; Tardif JC; White M
    Inflamm Res; 2024 May; 73(5):709-723. PubMed ID: 38546848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications.
    Cuomo A; Pirozzi F; Attanasio U; Franco R; Elia F; De Rosa E; Russo M; Ghigo A; Ameri P; Tocchetti CG; Mercurio V
    Curr Oncol Rep; 2020 Dec; 23(1):7. PubMed ID: 33263821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets.
    Reina-Couto M; Pereira-Terra P; Quelhas-Santos J; Silva-Pereira C; Albino-Teixeira A; Sousa T
    Front Physiol; 2021; 12():746494. PubMed ID: 34707513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management.
    Cuomo A; Paudice F; D'Angelo G; Perrotta G; Carannante A; Attanasio U; Iengo M; Fiore F; Tocchetti CG; Mercurio V; Pirozzi F
    Curr Heart Fail Rep; 2021 Aug; 18(4):191-199. PubMed ID: 34181210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer as an Individual Risk Factor for Heart Failure: A Review of Literature.
    Rivera Boadla ME; Sharma NR; Khan MH; Khurana S; Gulati A; Tan S; Sharma A; Hooda A; K C P
    Cureus; 2024 May; 16(5):e60592. PubMed ID: 38894762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory Cytokines, Immune Cells, and Organ Interactions in Heart Failure.
    Li H; Chen C; Wang DW
    Front Physiol; 2021; 12():695047. PubMed ID: 34276413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Molecular Mechanisms and Markers in Inflammatory Disorders.
    Vianello E; Galliera E
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Biomarkers in Cardio-Oncology.
    Ananthan K; Lyon AR
    J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?
    Chaikijurajai T; Choles HR; Tang WHW
    Curr Heart Fail Rep; 2020 Dec; 17(6):449-456. PubMed ID: 32939671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.
    Mamic P; Chaikijurajai T; Tang WHW
    J Mol Cell Cardiol; 2021 Mar; 152():105-117. PubMed ID: 33307092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample Mendelian randomization study.
    Wang Z; Yang F; Ma M; Bao Q; Shen J; Ye F; Xie X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):462. PubMed ID: 33115406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial Intelligence and Hypertension: Recent Advances and Future Outlook.
    Chaikijurajai T; Laffin LJ; Tang WHW
    Am J Hypertens; 2020 Nov; 33(11):967-974. PubMed ID: 32615586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Relationship Between CTRP Family and Coronary Artery Disease.
    Si Y; Fan W; Sun L
    Curr Atheroscler Rep; 2020 May; 22(6):22. PubMed ID: 32468164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
    Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
    Rabkin SW; Tang JKK
    Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player.
    Wesseling M; de Poel JHC; de Jager SCA
    ESC Heart Fail; 2020 Aug; 7(4):1488-1501. PubMed ID: 32424982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.